Cell death, metabolic diseases and cancer Group
Research
- Role of inflammatory signalling pathways and cell death in the development of metabolic liver disease and liver cancer
- Role of microRNAs in models of liver disease
- microRNAs as new biomarkers in patients with gastrointestinal cancer
- Biomarkers and artificial intelligence in the treatment of gastrointestinal tumours
Funding
- ERC: Consolidator Grant „How cellular suicide programmes control phase transitions in fatty liver disease and liver cancer - PHASE CONTROL“, 2018-2023
- BMG: Diagnosestellung und Risikostratifizierung von Lebererkrankungen mittels Deep Learning anhand von klinischen Routinedaten „DEEP LIVER“, 2020-2023
- DFG: Teilprojekt A01 im SFB 1382 „Microbiota and TLR-signalling in the development and recurrence of intrahepatic cholangiocarcinoma“, 2019-2023
- DFG: Sachbeihilfe „The role of miR-107-dependent signaling networks in hepatocarcinogenesis“, 2020-2023
- DFG: Sachbeihilfe "The role of RIPK1-dependent signaling cues in chronic liver disease and hepatocellular carcinoma", 2021-2024
- DFG: Sachbeihilfe "The role of A20 as a master switch for the regulation of multiple distinct cell death pathways in hepatocarcinogenesis", 2022-2024
- DFG: Schwerpunktprogramm "How ferroptosis and ferroptosis-response-pathways shape the immune landscape in pancreatic ductal adenocarcinoma (PDAC)", 2021-2024
- MKW: Multi-Omics Data Science (MODS) - Integrierte Datenanalyse zur Prädiktion, Prävention und Therapie metabolischer Systemstörungen MODS, 2021-2024
- DFG: Clinician Scientist Programm Zukunft gestalten für Clinician Scientists in präzisionsmetabolischer Medizin, 2023-2026
- BMBF: Transform Liver - Weiterentwicklung von Vision Transformern zur Entdeckung von Biomarkern bei Lebererkrankungen, 2023-2026
